Protocol Ledger

NCT04712643 · Phase III · ACTIVE NOT RECRUITING

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Interventional Phase III clinical trial protocol NCT04712643 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-12 Enrollment: 342 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04712643
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)342 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04712643
Protocol FieldVerified Registry Value
NCT IdentifierNCT04712643
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment342 participants (ACTUAL)
Registered Start Date2021-03-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04712643
Hospital Research SiteLocationSite Profile
Peking University First HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University People's HospitalBeijing, ChinaOpen Hospital Dossier ->
Beijing Tsinghua Changgung HospitalBeijing, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI